Is the optimal dose of preoperative statin associated with decreased end organ injury and better clinical outcome post cardiopulmonary bypass?

Trial Profile

Is the optimal dose of preoperative statin associated with decreased end organ injury and better clinical outcome post cardiopulmonary bypass?

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 04 May 2013

At a glance

  • Drugs Atorvastatin (Primary) ; HMG-CoA reductase inhibitors
  • Indications Coronary disorders; End-organ damage; Inflammation
  • Focus Biomarker; Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 21 Jan 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top